We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Amkor (AMKR) Q2 Earnings Gain From Strong Auto Demand?
Read MoreHide Full Article
Amkor Technology, Inc. (AMKR - Free Report) will report second-quarter 2018 results on Jul 30. In the last reported quarter, the company delivered a negative earnings surprise of 20.00%.
We observe that shares of Amkor have lost 17.7% in the past 12 months compared with its industry’s decline of 2.8%.
Let’s find out how things are shaping up for this announcement.
Factors to Consider
Amkor has been registering solid growth across all end markets, predominantly communications and automotive. Demand from all markets is expected to remain stable and so are revenues in the soon-to-be-reported quarter.
The company has been making efforts to channelize its resources in important growth areas like automotive and increase investments in Greater China. In this regard, Amkor invested huge amounts in the Shanghai factory and Greater China sales team to attract more business.
Automotive market growth is expected to be driven by increasing electronic content. Given its attractive value proposition for automotive customers, the company is poised to benefit going ahead and contribute significantly to top-line growth.
For the second quarter, Amkor expects revenues in the range of $990 million-$1.07 billion, up 2% year over year. Gross margin is expected within 14-16%. Earnings per share are expected in the range of (2 cents)-10 cents on a GAAP basis.
What Our Model Says
Amkor has a Zacks Rank #3 (Hold) and an Earnings ESP of 0.00%, a combination that makes surprise prediction difficult. This is because per our proven model, a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 to beat estimates. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
We don’t recommend Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement.
Here are some stocks that you may want to consider, as our model shows that these have the right combination of elements to deliver a positive earnings surprise.
Agilent Technologies (A - Free Report) has an Earnings ESP of +0.88% and a Zacks Rank #3.
Fortive Corporation (FTV - Free Report) has an Earnings ESP of +0.84 and a Zacks Rank #3.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Will Amkor (AMKR) Q2 Earnings Gain From Strong Auto Demand?
Amkor Technology, Inc. (AMKR - Free Report) will report second-quarter 2018 results on Jul 30. In the last reported quarter, the company delivered a negative earnings surprise of 20.00%.
We observe that shares of Amkor have lost 17.7% in the past 12 months compared with its industry’s decline of 2.8%.
Let’s find out how things are shaping up for this announcement.
Factors to Consider
Amkor has been registering solid growth across all end markets, predominantly communications and automotive. Demand from all markets is expected to remain stable and so are revenues in the soon-to-be-reported quarter.
The company has been making efforts to channelize its resources in important growth areas like automotive and increase investments in Greater China. In this regard, Amkor invested huge amounts in the Shanghai factory and Greater China sales team to attract more business.
Automotive market growth is expected to be driven by increasing electronic content. Given its attractive value proposition for automotive customers, the company is poised to benefit going ahead and contribute significantly to top-line growth.
For the second quarter, Amkor expects revenues in the range of $990 million-$1.07 billion, up 2% year over year. Gross margin is expected within 14-16%. Earnings per share are expected in the range of (2 cents)-10 cents on a GAAP basis.
What Our Model Says
Amkor has a Zacks Rank #3 (Hold) and an Earnings ESP of 0.00%, a combination that makes surprise prediction difficult. This is because per our proven model, a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 to beat estimates. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
We don’t recommend Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement.
Amkor Technology, Inc. Price and EPS Surprise
Amkor Technology, Inc. Price and EPS Surprise | Amkor Technology, Inc. Quote
Stocks to Consider
Here are some stocks that you may want to consider, as our model shows that these have the right combination of elements to deliver a positive earnings surprise.
AMETEK (AME - Free Report) has an Earnings ESP of +0.43% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Agilent Technologies (A - Free Report) has an Earnings ESP of +0.88% and a Zacks Rank #3.
Fortive Corporation (FTV - Free Report) has an Earnings ESP of +0.84 and a Zacks Rank #3.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>